February 5th 2025
While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient access to genetic counseling.
Ronald D. Alvarez, MD, MBA, analyzes recent changes to NCCN guidelines for ovarian cancer care and provides updates on the latest clinical trial data.